TFF Pharmaceuticals, Inc. (TFFP)
| Market Cap | 25.34M |
| Revenue (ttm) | 195,021 |
| Net Income (ttm) | -34.45M |
| Shares Out | 36.19M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,832 |
| Open | 0.700 |
| Previous Close | 0.702 |
| Day's Range | 0.700 - 0.725 |
| 52-Week Range | 0.620 - 7.700 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | 12.50 (+1,685.71%) |
| Earnings Date | May 9, 2023 |
About TFFP
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for TFFP stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 1,685.71% from the latest price.
News
TFF Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
FORT WORTH, Texas, March 07, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing inn...
TFF Pharmaceuticals to Participate in the 35th Annual Roth Conference
FORT WORTH, Texas, March 06, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug pro...
3 Bargain Stocks Worth Buying at These 52-Week Lows
Who doesn't love a bargain? We look for deals in many places.
TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer
Dr. Harlan Weisman and recently appointed Chief Medical Officer Dr. Zamaneh Mikhak to Provide an Overview of the Corporate Strategy and 2023 Objectives
TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer
FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...
TFF Pharmaceuticals Announces Leadership Transition
Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors
TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering
Underwriters Exercise Their Option in Full Underwriters Exercise Their Option in Full
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TFF Pharmaceuticals, Inc. - TFFP
New York, New York--(Newsfile Corp. - November 19, 2022) - Pomerantz LLP is investigating claims on behalf of investors of TFF Pharmaceuticals, Inc. ("TFF" or the "Company") (NASDAQ: TFFP). Such inves...
TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants
FORT WORTH, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...
TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
FORT WORTH, Texas, Nov. 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...
TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Clinical Proof-of-Concept Demonstrated in Compassionate Use in Two Case Studies with Voriconazole Inhalation Powder (TFF VORI)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TFF Pharmaceuticals, Inc. - TFFP
NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TFF Pharmaceuticals, Inc. ("TFF" or the "Company") (NASDAQ: TFFP). Such investors are advised t...
TFF Pharmaceuticals to Hold Third Quarter 2022 Financial and Business Results Conference Call on November 14, 2022
Company conference call and webcast at 4:30 PM ET
TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics
Administration of dry powders will utilize Aptar Pharma's Unidose (UDS) Powder Nasal Spray System
TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program
Marks the Second Patient to Clinically Benefit from Administration of Voriconazole Inhalation Powder (TFF VORI) Using Thin Film Freezing-Based Technology
TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Clinical Programs
FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...
TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting
Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting's Special Poster Collections
TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference
FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug pro...
TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting
Two Abstracts Selected for Presentation as part of the Meeting's Special Poster Collections
TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation
Dr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia presented results from compassionate use of treating pulmonary fungal infections in a lung transplant patient
TFF Pharmaceuticals to Participate at The H.C. Wainwright 24th Annual Global Investment Conference
FORT WORTH, Texas, Sept. 06, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug pro...
TFF Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance
TFF Pharmaceuticals to Hold Second Quarter 2022 Financial and Business Results Conference Call on August 11, 2022
Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET
TFF Pharmaceuticals Expands R&D Operations with New Austin Facility
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects
TFF Pharmaceuticals to Participate at The JMP Securities Life Sciences Conference
FORT WORTH, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug prod...